Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 1,999 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: carboplatin Clear all
Terminated Phase 3 Interventional Results available

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

NCT00004859
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, thalidomide, radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
235
States / cities
Fort Smith, Arkansas • Modesto, California • Salinas, California + 168 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Nov 7, 2026, 10:15 AM EST
Completed Phase 3 Interventional Results available

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00951496
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Stage II Fallopian Tube Cancer AJCC v6 and v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Bevacizumab, Carboplatin, Cisplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
1,560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
503
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 332 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Nov 7, 2026, 10:15 AM EST
Completed Phase 1 Interventional

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

NCT03846310
View directory record Official record
Conditions
Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
Interventions
Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Tucson, Arizona • Fort Myers, Florida • Tavares, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Nov 7, 2026, 10:15 AM EST
Active, not recruiting No phase listed Observational

Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases

NCT07485179
View directory record Official record
Conditions
Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
Initiation of pembrolizumab, Initiation of chemotherapy
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 7, 2026, 10:15 AM EST
Completed Phase 2 Interventional Results available

First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin

NCT00316186
View directory record Official record
Conditions
Lung Cancer, Small Cell
Interventions
topotecan, carboplatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
12
States / cities
Tucson, Arizona • Concord, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Nov 7, 2026, 10:15 AM EST
Active, not recruiting Phase 3 Interventional

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

NCT05502237
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Zimberelimab, Domvanalimab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Whittier, California • Washington D.C., District of Columbia • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Nov 7, 2026, 10:15 AM EST
Completed Phase 1Phase 2 Interventional

Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer

NCT00277069
View directory record Official record
Conditions
Breast, Cancer
Interventions
Carboplatin, Capecitabine, Vinorelbine
Drug · Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Nov 7, 2026, 10:15 AM EST
Active, not recruiting Phase 2 Interventional

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

NCT04858269
View directory record Official record
Conditions
Head Neck Cancer, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma
Interventions
Pembrolizumab, Carboplatin, Paclitaxel
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Nov 7, 2026, 10:15 AM EST
Terminated Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

NCT04832854
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Atezolizumab, Tiragolumab, Carboplatin, Cisplatin, Pemetrexed, Gemcitabine, Paclitaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Duarte, California • Los Angeles, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Nov 7, 2026, 10:15 AM EST
Not listed Phase 2 Interventional

Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

NCT00777673
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
Drug
Lead sponsor
University of Tennessee Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Nov 7, 2026, 10:15 AM EST
Completed Phase 2 Interventional Results available

Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer

NCT00068341
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, docetaxel
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
4
States / cities
Little Rock, Arkansas • Los Angeles, California • Pomona, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Nov 7, 2026, 10:15 AM EST
Completed Phase 1 Interventional

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

NCT04649385
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BGB-15025, Tislelizumab, Carboplatin, Cisplatin, Pemetrexed, Oxaliplatin, Capecitabine, Paclitaxel, nab-paclitaxel
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
New York, New York • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Nov 7, 2026, 10:15 AM EST
Completed Not applicable Interventional

High Dose Chemotherapy and Autologous Transplant for Neuroblastoma

NCT01526603
View directory record Official record
Conditions
Neuroblastoma
Interventions
Carboplatin, Autologous stem cell infusion, Granulocyte colony stimulating factor, Radiation therapy, Isotretinoin (13-cis-retinoic acid), Melphalan, Etoposide
Drug · Biological · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Nov 7, 2026, 10:15 AM EST
Completed Phase 2 Interventional Results available

Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

NCT00003631
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, carboplatin, carmustine, cyclophosphamide, cytarabine, etoposide, ifosfamide, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Nov 7, 2026, 10:15 AM EST
Completed Phase 1 Interventional

Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer

NCT00003294
View directory record Official record
Conditions
Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, amifostine trihydrate, carboplatin, paclitaxel
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Nov 7, 2026, 10:15 AM EST
Withdrawn Phase 2 Interventional

RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC

NCT04849377
View directory record Official record
Conditions
Human Papillomavirus (HPV), Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
RT 50 Gy, RT 54 GY, RT 60 GY, Induction Therapy, Carboplatin, Cisplatin 200, Cisplatin 240
Radiation · Other · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Nov 7, 2026, 10:15 AM EST
Active, not recruiting Phase 2 Interventional

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

NCT04592237
View directory record Official record
Conditions
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8
Interventions
Cabazitaxel, Carboplatin, Cetrelimab, Niraparib
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 7, 2026, 10:15 AM EST
Completed Phase 1 Interventional

Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors

NCT00193583
View directory record Official record
Conditions
Cancer
Interventions
Topotecan, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Nov 7, 2026, 10:15 AM EST
Active, not recruiting Phase 2 Interventional Results available

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

NCT01525966
View directory record Official record
Conditions
Inflammatory Breast Cancer, Stage IIA Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer, Stage IIB Breast Cancer, Estrogen Receptor Negative, Progesterone Receptor Negative, HER2/Neu Negative
Interventions
carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 7, 2026, 10:15 AM EST
Completed Phase 2 Interventional Results available

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

NCT00861705
View directory record Official record
Conditions
Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Bevacizumab, Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
448
States / cities
Jonesboro, Arkansas • Rogers, Arkansas • Berkeley, California + 309 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 7, 2026, 10:15 AM EST
Completed Phase 3 Interventional Results available

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

NCT02163694
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Veliparib Placebo, Veliparib, Carboplatin, Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
56
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Duarte, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Nov 7, 2026, 10:15 AM EST
Active, not recruiting Phase 3 Interventional Results available

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT01167712
View directory record Official record
Conditions
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Bevacizumab, Carboplatin, Computed Tomography, Paclitaxel, Therapeutic Conventional Surgery
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
559
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 374 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Nov 7, 2026, 10:15 AM EST
Completed Phase 2 Interventional Results available

Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

NCT03916419
View directory record Official record
Conditions
Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
Interventions
ViewRay MR-Linear Accelerator, Radiation therapy, Paclitaxel, Carboplatin AUC, Durvalumab
Device · Radiation · Drug + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 7, 2026, 10:15 AM EST
Completed Phase 1 Interventional

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

NCT00005065
View directory record Official record
Conditions
Stage IIIA Non-small Cell Lung Cancer
Interventions
paclitaxel, carboplatin, motexafin gadolinium, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Nov 7, 2026, 10:15 AM EST